AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22407658 — intervention group
Group type: EXPERIMENTAL
Intervention: behavioral migraine management + β‐blocker
Number of subjects: 177
Study 20486816 — intervention group
Group type: EXPERIMENTAL
Intervention: Death certificates listing COPD as cause of death
Number of subjects: 317
Study 20486816 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudicated cause of death
Number of subjects: 317
Study 20486816 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD exacerbation as cause of death
Number of subjects: 317
Study 20486816 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of cause of death listings
Number of subjects: 317
Study 20486816 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined primary and secondary listing on death certificates
Number of subjects: 317
Study 18841411 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-R15 measured at clamping phase
Number of subjects: 29
Study 18841411 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ICG-R15
Number of subjects: 29
Study 18841411 — intervention group
Group type: EXPERIMENTAL
Intervention: Total clamp time
Number of subjects: 29
Study 18841411 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood loss
Number of subjects: 29
Study 15980363 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Escherichia coli phage T4 dose (10(3) PFU/ml)
Number of subjects: 15
Study 15980363 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Escherichia coli phage T4 dose (10(5) PFU/ml)
Number of subjects: 15
Study 15980363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 12050836 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg to 5 mg of intravenous morphine
Number of subjects: 11
Study 10075332 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein intake
Number of subjects: 260
Study 10075332 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 260
Study 10075332 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine
Number of subjects: 260
Study 10075332 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestudy use of supplemental B vitamins
Number of subjects: 260
Study 1704534 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual chamber pacing
Number of subjects: 40
Study 1704534 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 40
Study 111288 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg, 1.5 mg, or 2.5 mg physostigmine i.v.
Number of subjects: 28
Study 111288 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral choline chloride (8 g/day for 3 weeks or 16 g/day for 1 week)
Number of subjects: 28
Study 111288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 6360198 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (10000 i.u. subcutaneously twice daily) throughout pregnancy and labour
Number of subjects: 40
Study 6360198 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 30667494 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based symptom monitoring during chemotherapy
Number of subjects: 0
Study 30667494 — intervention group
Group type: COMPARATOR
Intervention: Standard scheduled imaging after treatment
Number of subjects: 0
Study 29549006 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 124
Study 29549006 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study 29549006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 124
Study 26708301 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone-only pill (4 mg) with scheduled 24-h delays in tablet intake
Number of subjects: 130
Study 26708301 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular intake of drospirenone-only pill
Number of subjects: 130
Study 24550202 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a rapid response team
Number of subjects: 439
Study 24550202 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardizing defibrillators
Number of subjects: 439
Study 24550202 — intervention group
Group type: EXPERIMENTAL
Intervention: Debriefing
Number of subjects: 439
Study 24550202 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training
Number of subjects: 439
Study 24550202 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to quality improvement
Number of subjects: 439
Study 24550202 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 439
Study 24550202 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of CPR assist technology
Number of subjects: 439
Study 21797805 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept plus nbUVB (50 mg once a week + nbUVB three times weekly for 4 weeks)
Number of subjects: 75
Study 21797805 — intervention group
Group type: COMPARATOR
Intervention: Etanercept monotherapy (50 mg once a week)
Number of subjects: 75
Study 21797805 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept plus nbUVB (for patients with high adherence)
Number of subjects: 75
Study 21797805 — intervention group
Group type: COMPARATOR
Intervention: Etanercept monotherapy (for patients with high adherence)
Number of subjects: 75
Study 20864251 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical botulinum toxin type A (BoNTA) injection, >100 U
Number of subjects: 217
Study 20864251 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical botulinum toxin type A (BoNTA) injection
Number of subjects: 217
Study 20864251 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical botulinum toxin A (BoNTA) injection
Number of subjects: 217
Study 17548750 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram hydrobromide for up to 12 weeks
Number of subjects: 1447
Study 15781750 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 350
Study 15781750 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg IV
Number of subjects: 350
Study 15781750 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 5.0 mg IV
Number of subjects: 350
Study 15781750 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux (combined groups)
Number of subjects: 350
Study 15781750 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 350
Study 12045070 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal laboratory training (ALT)
Number of subjects: 18
Study 12045070 — intervention group
Group type: COMPARATOR
Intervention: Control (no ALT)
Number of subjects: 18
Study 9468364 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant gp160 immunization
Number of subjects: 40
Study 9468364 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine monochemotherapy
Number of subjects: 40
Study 9468364 — intervention group
Group type: COMPARATOR
Intervention: Potent antiviral combination therapy
Number of subjects: 40
Study 9468364 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with HIV gp160 antigen
Number of subjects: 40
Study 9468364 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy alone
Number of subjects: 40
Study 9468364 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization alone
Number of subjects: 40
Study 9468364 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunized group
Number of subjects: 40
Study 7895549 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g chili orally with 200 ml water followed by 600 mg aspirin BP with 200 ml water
Number of subjects: 18
Study 7895549 — intervention group
Group type: COMPARATOR
Intervention: 200 ml water followed by 600 mg aspirin BP with 200 ml water
Number of subjects: 18
Study 2651663 — intervention group
Group type: EXPERIMENTAL
Intervention: Local instillation of metronidazole and cephazolin intraperitoneally and interparietally (group A)
Number of subjects: 100
Study 2651663 — intervention group
Group type: COMPARATOR
Intervention: No local antibiotic therapy (group B)
Number of subjects: 100
Study 2651663 — intervention group
Group type: EXPERIMENTAL
Intervention: Local instillation of metronidazole and cephazolin (group A)
Number of subjects: 100
Study 82987 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 9
Study 82987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 82987 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 9
Study 31937049 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive management group (nutritional support, psychological intervention, pulmonary rehabilitation exercise)
Number of subjects: 260
Study 31937049 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine treatment including smoking quitting persuasion, vaccination, oxygen therapy and standardized medication)
Number of subjects: 260
Study 31130571 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 14
Study 31130571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 27896411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (2 mg/kg followed by continuous infusions of 3 mg/kg/h)
Number of subjects: 90
Study 27896411 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (same volume as lidocaine)
Number of subjects: 90
Study 26506852 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental vitamin D3 (4,000 IU/day)
Number of subjects: 20
Study 26506852 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 mg of cellulose)
Number of subjects: 20
Study 26506852 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 nmol 1α,25(OH)2D3
Number of subjects: 20
Study 26506852 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 nmol 1α,25(OH)2D3
Number of subjects: 20
Study 23673791 — intervention group
Group type: EXPERIMENTAL
Intervention: Online health intervention for HIV risk reduction
Number of subjects: 0
Study 21439850 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine (1,000 mg/day for 12 weeks)
Number of subjects: 36
Study 21439850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19231487 — intervention group
Group type: EXPERIMENTAL
Intervention: rPAF‐AH (1 mg/kg)
Number of subjects: 600
Study 19231487 — intervention group
Group type: EXPERIMENTAL
Intervention: rPAF‐AH (5 mg/kg)
Number of subjects: 600
Study 19231487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 17214906 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-navigated minimally invasive total hip surgery (MIS)
Number of subjects: 0
Study 17214906 — intervention group
Group type: COMPARATOR
Intervention: Conventional total hip arthroplasty (THA)
Number of subjects: 0
Study 14871165 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injections
Number of subjects: 0
Study 14871165 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 0
Study 14871165 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see policy
Number of subjects: 0
Study 14871165 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see policy vs Corticosteroid injections
Number of subjects: 0
Study 14871165 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy vs Corticosteroid injections
Number of subjects: 0
Study 14871165 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy vs Wait-and-see policy
Number of subjects: 0
Study 10982947 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated dry socket packing (9% eugenol, 36% balsam of Peru, 55% petroleum jelly) placed immediately after extraction
Number of subjects: 100
Study 10982947 — intervention group
Group type: COMPARATOR
Intervention: No medicated packing (control group)
Number of subjects: 100
Study 8624004 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic intubation
Number of subjects: 131
Study 8624004 — intervention group
Group type: COMPARATOR
Intervention: Laryngoscopic intubation
Number of subjects: 131
Study 8624004 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 131
Study 1558996 — intervention group
Group type: EXPERIMENTAL
Intervention: IB + BD
Number of subjects: 24
Study 1558996 — intervention group
Group type: EXPERIMENTAL
Intervention: IN + BD
Number of subjects: 24
Study 1558996 — intervention group
Group type: EXPERIMENTAL
Intervention: IB alone
Number of subjects: 24
Study 1558996 — intervention group
Group type: EXPERIMENTAL
Intervention: IN alone
Number of subjects: 24
Study 1558996 — intervention group
Group type: EXPERIMENTAL
Intervention: BD alone
Number of subjects: 24
Study 1558996 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 3926568 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 70
Study 3926568 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 70
Study 30623563 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide (10 μg subcutaneously)
Number of subjects: 30
Study 30623563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29345047 — intervention group
Group type: EXPERIMENTAL
Intervention: Prercorded maternal heart sounds (n = 32)
Number of subjects: 62
Study 29345047 — intervention group
Group type: COMPARATOR
Intervention: Routine care (n = 30)
Number of subjects: 62
Study 28700489 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (a bolus dose of 0.5 μg/kg and then an infusion of 0.5 μg/kg/h)
Number of subjects: 29
Study 28700489 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 29
Study 28700489 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 29
Study 26323156 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiawei Bazhen decoction combined with oxytocin
Number of subjects: 180
Study 26323156 — intervention group
Group type: COMPARATOR
Intervention: oxytocin
Number of subjects: 180
Study 26323156 — intervention group
Group type: COMPARATOR
Intervention: blank control group
Number of subjects: 180
Study 23957521 — intervention group
Group type: EXPERIMENTAL
Intervention: Three different methods for jointly modeling clinical safety and efficacy endpoints (specific methods: copula method, conditional distributions, hierarchical model)
Number of subjects: 0
Study 21394832 — intervention group
Group type: EXPERIMENTAL
Intervention: Email guidance in internet-based cognitive-behavioural self-care treatment
Number of subjects: 71
Study 21394832 — intervention group
Group type: EXPERIMENTAL
Intervention: Email support
Number of subjects: 71
Study 18067518 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-start strategy (FS)
Number of subjects: 7
Study 18067518 — intervention group
Group type: COMPARATOR
Intervention: Even-pace strategy (ES)
Number of subjects: 7
Study 18067518 — intervention group
Group type: COMPARATOR
Intervention: Slow-start strategy (SS)
Number of subjects: 7
Study 16384561 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus L-carnitine (2g/day)
Number of subjects: 52
Study 16384561 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (20 mg/day)
Number of subjects: 52
Study 14557969 — intervention group
Group type: EXPERIMENTAL
Intervention: C+E (Clarithromycin + Ethambutol)
Number of subjects: 160
Study 14557969 — intervention group
Group type: EXPERIMENTAL
Intervention: C+R (Clarithromycin + Rifabutin)
Number of subjects: 160
Study 14557969 — intervention group
Group type: EXPERIMENTAL
Intervention: C+E+R (Clarithromycin + Ethambutol + Rifabutin)
Number of subjects: 160
Study 10896763 — intervention group
Group type: EXPERIMENTAL
Intervention: Real foods
Number of subjects: 0
Study 10896763 — intervention group
Group type: EXPERIMENTAL
Intervention: Food photographs
Number of subjects: 0
Study 10896763 — intervention group
Group type: EXPERIMENTAL
Intervention: Food models
Number of subjects: 0
Study 10896763 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasting method
Number of subjects: 0
Study 10896763 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-year-olds
Number of subjects: 0
Study 8618399 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC+HCFU
Number of subjects: 149
Study 8618399 — intervention group
Group type: COMPARATOR
Intervention: MMC
Number of subjects: 149
Study 1358132 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of nilvadipine
Number of subjects: 30
Study 1358132 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of nilvadipine
Number of subjects: 30
Study 1358132 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 30
Study 2981086 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (30, 60, 90, and 120 mU/kg, iv bolus injection)
Number of subjects: 0
Study 2981086 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged infusion of oxytocin (90 mU/kg . h)
Number of subjects: 0
Study 2981086 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment with oxytocin (50 mU/kg, iv bolus dose, followed by an infusion of 50 mU/kg . h)
Number of subjects: 0
Study 2981086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31597504 — intervention group
Group type: EXPERIMENTAL
Intervention: High-response CRF group
Number of subjects: 80
Study 31597504 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-response CRF group
Number of subjects: 80
Study 31597504 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-response CRF group
Number of subjects: 80
Study 31597504 — intervention group
Group type: EXPERIMENTAL
Intervention: High response CRF
Number of subjects: 80
Study 29695765 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of gemcitabine (1000 mg/m2), nab-paclitaxel (150 mg/m2), and bevacizumab (15 mg/kg)
Number of subjects: 110
Study 29695765 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of gemcitabine, nab-paclitaxel, and bevacizumab
Number of subjects: 110
Study 27456384 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-493 (200 mg) plus ABT-530 (120 mg) for 12 weeks in GT1 patients
Number of subjects: 82
Study 27456384 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-493 (300 mg) plus ABT-530 (120 mg) with RBV (800 mg once daily) for 12 weeks in GT3 patients
Number of subjects: 82
Study 27456384 — intervention group
Group type: COMPARATOR
Intervention: ABT-493 (300 mg) plus ABT-530 (120 mg) without RBV for 12 weeks in GT3 patients
Number of subjects: 82
Study 24916050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive (PI) strategy
Number of subjects: 1754
Study 24916050 — intervention group
Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 1754
Study 22361711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pozarevac area with mean Mg level of 42 mg L(‐1)
Number of subjects: 90
Study 22361711 — intervention group
Group type: COMPARATOR
Intervention: Grocka area with mean Mg level of 11 mg L(‐1)
Number of subjects: 90
Study 22361711 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for confounders (age, gender, BMI)
Number of subjects: 90
Study 20860504 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux, 2.5 mg once daily for 45 days
Number of subjects: 3002
Study 20860504 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 45 days
Number of subjects: 3002
Study 17971707 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (3 g twice daily)
Number of subjects: 100
Study 17971707 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg daily)
Number of subjects: 100
Study 17971707 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (fish oil and fenofibrate)
Number of subjects: 100
Study 17971707 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 100
Study 15695126 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 1558
Study 15695126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1558
Study 12832242 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 or 100 mg daily)
Number of subjects: 747
Study 12832242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 747
Study 11262606 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% taurolidine
Number of subjects: 110
Study 11262606 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% gentamicin
Number of subjects: 110
Study 11262606 — intervention group
Group type: COMPARATOR
Intervention: Vehicle eyedrops
Number of subjects: 110
Study 11262606 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 110
Study 8435323 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetholone 2 mg/kg/d p.o. daily for 4 months
Number of subjects: 134
Study 8435323 — intervention group
Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 134
Study 3314972 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser treatment with contiguous or overlapping laser spots
Number of subjects: 220
Study 3314972 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser treatment at twice the minimum blanching power
Number of subjects: 220
Study 3314972 — intervention group
Group type: EXPERIMENTAL
Intervention: Neodymium (Nd) YAG laser treatment
Number of subjects: 220
Study 31994178 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 0
Study 31994178 — intervention group
Group type: COMPARATOR
Intervention: Physicians' choice
Number of subjects: 0
Study 28679199 — intervention group
Group type: EXPERIMENTAL
Intervention: USG II/IHN plus GFN block
Number of subjects: 80
Study 28679199 — intervention group
Group type: COMPARATOR
Intervention: USG II/IHN block alone (Control Group)
Number of subjects: 80
Study 27288376 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive internet platform with coach support
Number of subjects: 2600
Study 27288376 — intervention group
Group type: COMPARATOR
Intervention: Static internet platform with basic health information
Number of subjects: 2600
Study 26908742 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of the live attenuated tetravalent dengue vaccine TV003
Number of subjects: 48
Study 26908742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 24382059 — intervention group
Group type: EXPERIMENTAL
Intervention: Long mini-implant (11 mm, 2 mm diameter)
Number of subjects: 20
Study 24382059 — intervention group
Group type: COMPARATOR
Intervention: Short mini-implant (9 mm, 2 mm diameter) - Control group
Number of subjects: 20